Optimind Pharma Corp.
OMND
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.03% | 46.34% | -61.18% | -34.81% | -56.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.03% | 46.34% | -61.18% | -34.81% | -56.08% |
| Cost of Revenue | -18.56% | -41.07% | -54.87% | -93.55% | -51.98% |
| Gross Profit | 16.33% | 428.95% | -72.73% | 394.74% | -59.50% |
| SG&A Expenses | -78.13% | -30.66% | -62.11% | 22.31% | -65.47% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -54.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.62% | -34.88% | -73.28% | -9.21% | -63.99% |
| Operating Income | 92.88% | 49.65% | 74.62% | 1.27% | 65.79% |
| Income Before Tax | 91.37% | 56.21% | 75.97% | 63.92% | 67.43% |
| Income Tax Expenses | -- | -- | -- | -51.16% | -- |
| Earnings from Continuing Operations | 91.37% | 56.21% | 75.97% | 64.26% | 67.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.37% | 56.21% | 75.97% | 64.26% | 67.43% |
| EBIT | 92.88% | 49.65% | 74.62% | 1.27% | 65.79% |
| EBITDA | -- | -- | -- | 1.31% | 66.62% |
| EPS Basic | 87.50% | 57.14% | 80.00% | 66.23% | 68.00% |
| Normalized Basic EPS | 100.00% | 66.67% | 78.95% | -87.50% | 62.50% |
| EPS Diluted | 87.50% | 57.14% | 80.00% | 66.23% | 68.00% |
| Normalized Diluted EPS | 100.00% | 66.67% | 78.95% | -87.50% | 62.50% |
| Average Basic Shares Outstanding | 11.92% | 11.40% | 19.32% | 6.63% | 4.09% |
| Average Diluted Shares Outstanding | 11.92% | 11.40% | 19.32% | 6.63% | 4.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
